Jubilant Ingrevia Ltd Q2 FY2023 Concall Summary

Key Takeaways

• Temporary headwinds mask underlying strength: Revenue grew 7% YoY, but EBITDA margin contracted sharply as two acute shocks — a ₹140 crore FSA coal unavailability penalty and a vitamin B3 demand collapse — hit simultaneously. Management frames both as short-term and resolvable by Q4.
• Specialty Chemicals is the growth engine: The segment grew 63% YoY, with over 65% of that growth volume-driven, powered by Pyridine and its derivatives riding a China-plus shift. The CDMO pipeline is also scaling, with 7 commercial pharma molecules now active.
• Nutrition & Health Solutions is the drag: Revenue de-grew 36% as post-flu poultry culling left vitamin B3 (Niacinamide) volumes and realizations 12–14% below FY22 levels. Full normalization is not expected until Q1 next year.
• The coal crisis has a hard deadline: The ₹140 crore H1 impact from non-availability of contracted FSA coal is the single largest margin headwind. Management is "very, very confident" the issue will be resolved by end of Q3 or beginning of Q4, with FSA supply expected from 1 December or 1 January.
• What to watch next quarter: Whether FSA coal actually resumes in December, the pace of vitamin B3 volume recovery, and the commissioning of new CDMO and Acetic Anhydride capacities that are supposed to drive the H2 rebound.

The Two Margin Shocks

• FSA coal unavailability: The company has a 5-year fixed-price contract with the Government for coal supply. That supply was deferred, not cancelled, forcing Jubilant to buy market coal at ~₹12,000/tonne versus the contracted ₹5,000–6,000/tonne. The differential created a ~₹140 crore EBITDA hit in H1 that cannot be passed on to customers because it is a company-specific penalty, not a general industry cost increase.
• General coal price pass-through: The broader market price increase of coal (from ₹6,000 to ₹12,000/tonne) added another ₹70–80 crore of cost, but this was largely recovered in product pricing since it affected all industry players equally.
• Power & fuel cost ratio: The combined effect pushed power and fuel costs to 15–16% of sales, nearly double the normalized 8–8.5% run-rate.
• Vitamin B3 demand collapse: Niacinamide volumes and realizations fell sharply because global poultry flocks were culled due to flu, creating an inventory overhang across the value chain. The recovery timeline is biological: farms take 3–4 months to restock after culling, plus another 1–2 months for inventory liquidation, putting full normalization in Q1 FY24.
• Nutrition segment EBITDA: The segment's EBITDA and margin declined primarily on lower Niacinamide sales volumes, dragging overall company profitability.

Rajesh Srivastava: "The temporary situation, the 2 realities which we are talking is very short term, which is the coal price increase. And secondly, is the temporary impact of our vitamin B3 business. Rest all, the business is really standing very strong, as you can see with the results."

Specialty Chemicals: The Growth Engine

• Volume-led surge: The segment's 63% YoY revenue growth was driven ~42–43% by volumes; more than 65% of the growth was volume-driven, not price-driven.
• Pyridine dominance: Growth is primarily coming from Pyridine and Pyridine derivatives, fueled by the China-plus sourcing shift, continuous introduction of new products, and market share gains in products where Jubilant does not yet hold 70–80% share. Overall market demand is also expanding.
• CDMO scaling up: Commercial-scale product count increased to 7 in pharma (from 5) and about 3 in agrochemicals (from 2). All dedicated CDMO capacities are fully utilized, which is why 2 non-GMP capacities and 1 GMP capacity are being readied this quarter to service increased volumes.
• CDMO revenue contribution: Currently close to a double-digit percentage of Specialty Chemicals revenue, with significant improvement expected as pipeline products come through.
• New capacity ramp: Management expects new CDMO capacities to be utilized within a short period (~2 quarters per an analyst's math), and every investment is targeted to deliver asset turnover close to 2x plus, reaching 70–90% utilization within about a year.
• Diketene recovery path: Utilization is currently at 40–50% due to low demand from a large Indian agrochemical customer and weakness in Dye and Packaging industries. Demand normalization is expected by Q4 or Q1 next year, with management confident of touching 80–100% capacity by Q4. Phase 2 expansion with 3–4 new products is planned for FY24.

Rajesh Srivastava: "We have not achieved, let's say, 70% or 80% market share in each of our products. So, there is enough room for us to grow within the pyridine and pyridine derivatives also."

Chemical Intermediates: Mixed Signals

• Acetic Anhydride strength: Volumes grew double-digit YoY across all regions — domestic (new paracetamol and agrochemical capacity in India), Europe (rising demand, no competitor capacity additions), and Southeast Asia. Jubilant is the only company that expanded anhydride capacity 2 years ago, and the upcoming Q4 plant will be the only global capacity expansion. A new use in food acetylation in Europe is also driving demand.
• Acetic Acid inventory hit: Segment EBITDA did not reflect the volume growth because Acetic Acid prices fell from $745 to $620 during the quarter, causing a 20-day stock valuation reduction on a gradual basis. Once Acetic Acid prices normalize, normalized EBITDA will become visible.
• Ethyl Acetate strategy: Demand is lower due to China dumping excess production in Europe and weaker packaging industry demand in India. Jubilant focuses only on select quality-sensitive customers, not large volumes, because "this is not a product where we feel that we can make good money." New value-added products like Propionic Anhydride are being developed using existing capacity with debottlenecking.
• Revenue guidance difficulty: Management declined to give revenue guidelines for the segment because input prices (methanol, Acetic Acid) fluctuate drastically — Acetic Acid was $1,000 last year and is $550 today, making revenue projections unreliable.

Rajesh Srivastava: "...globally, nobody is increasing capacity. Jubilant is the only company where we have increased the capacity of anhydride 2 years before. And this plant, which will come up in Q4 will be the only capacity expansion of anhydride in the global expansion."

Balance Sheet & Working Capital

• Working capital spike: Net working capital increased due to two factors: a strategic inventory build of 2 products to gain market share and profitability over the next 2 quarters (a 5–6 month event), and a temporary reduction in creditors due to procurement of domestic ethanol where creditor terms are shorter. Normalization back to the 15–16% range is expected in 3–4 months (by December/January).
• Debt increase: Net debt rose to ₹280 crore, primarily to fund the working capital increase. This is short-term borrowing with enough headroom, and management expects to bring overall borrowing to a controlled level by end of this year as H2 performance improves significantly.
• Finance cost reduction: Finance costs fell to ₹5.1 crore from ₹7.16 crore YoY on account of repayment of high-cost long-term loans and lower average debt utilization.
• Credit rating upgrade: India Ratings upgraded the long-term debt rating to AA+ stable from AA stable during the quarter.

Energy De-risking & Sustainability

• FSA coal resolution: Management is "very, very confident" the FSA coal issue will be resolved by end of Q3 or beginning of Q4, with supply expected from 1 December or absolutely from 1 January. The Government is under pressure from various industries to supply. The contract is with the Government for 5 years, making cancellation unlikely — this is a deferment, not a cancellation.
• Long-term energy strategy: The company is taking a long-term view to de-risk from coal dependency, with a strategy to minimize future impact taking shape over 2–3 quarters.
• Solar/renewable energy: Solar sourcing has already started at one site in Maharashtra, with serious work underway to start in Gujarat and UP. Management expects clarity and maturity on the energy mix in about 9–12 months.
• EcoVadis rating: Achieved a CSA assessment score of 93% with gold rating during the quarter.

Rajesh Srivastava: "First of all, you should know that this contract is between us and Government. So, this is absolutely unlikely that we will not get FSA coal. It is definitely the deferment, not the canceling. And we have a contract for 5 years. So, it's absolutely not possible that we will not get."

Revenue Mix Ambition

• 65% target by FY27: Management continues efforts to improve the revenue mix of Specialty and Nutrition segments to 65% by FY27 from 46% in FY22, believing this to be a key driver for overall margin improvements.
• CapEx allocation aligned: Most new growth CapEx is in Specialty Chemicals and Nutrition; within Chemical Intermediates, major CapEx is only on Anhydride and Green Acetic Acid. The ongoing growth CapEx plan totals ₹2,050 crore during FY22 to FY25.
• Specialty Chemicals 50% target: Existing performance is in line with the stated growth trajectory, and the FY25 target is achievable as shown in the investor presentation.
• Breakdown not provided: When asked for the split of the 50% revenue target between Specialty Chemicals and Nutrition, management did not have the exact number and offered to revert later.

Guidance & Commitments

Key Metrics